Compare Medpace Holdings Inc (MEDP) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs PubMatic Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while PubMatic Inc trades at $13 (market cap $607.48M). The key difference: Medpace Holdings Inc is far larger — about 24.8× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | PUBM | |
|---|---|---|
Market Cap | $15.08B | $607.48M |
Sector | Technology | Technology |
52-Week High | $620.59 | $13.83 |
52-Week Low | $308.88 | $6.28 |
Enterprise Value | $14.55B | $504.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
PUBM trades at $13.07, up 2.67% today, with a bullish technical signal from moving averages and oversold RSI conditions. The company reported a net loss of -$14.46M in 2025 despite beating Q1 2026 EPS estimates, with revenue at $282.93M. Recent news highlights product launches like AgenticOS and partnerships expanding its AI-powered ad tech reach, while analyst consensus is evenly split between Buy and Hold.
The outlook is mixed: strong cash flow and innovation in AI advertising support growth potential, but persistent negative margins and high P/E of 132 pose valuation risks. Upside exists if upcoming Q2 2026 earnings beat expectations, though competitive and macroeconomic pressures remain headwinds for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
